The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English
Deutsch
English
Unsere Publikationen
Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
Link
https://doi.org/10.1371/journal.pone.0173353
Tags
Multiple Sklerose
MS Behandlung
Jahr
2017
Autoren
Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T.
Verlag
PLoS ONE 2017;12(5).
Zum Eintrag
Treatment optimization in multiple sclerosis: how do we apply emerging evidence?
Link
https://doi.org/10.1080/1744666x.2017.1292135
Tags
Multiple Sklerose
MS Behandlung
Jahr
2017
Autoren
Ziemssen T, Thomas K.
Verlag
Expert Rev Clin Immunol 2017;13(6):509-511.
Zum Eintrag
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Link
https://doi.org/10.1186/s12974-017-0945-z
Tags
Multiple Sklerose
MS Behandlung
Jahr
2017
Autoren
Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.
Verlag
J Neuroinflammation. 2017 Aug 31;14(1):172.
Zum Eintrag
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question
Link
https://doi.org/10.1080/14737175.2017.1340831
Tags
Multiple Sklerose
MS Behandlung
Jahr
2017
Autoren
D'Amico E, Ziemssen T, Cottone S.
Verlag
Expert Rev Neurother 2017;17(9):847-849.
Zum Eintrag
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: An update on the clinical trial evidence and data from the real world
Link
https://doi.org/10.1177/1756285617722706
Tags
Multiple Sklerose
MS Behandlung
Jahr
2017
Autoren
Ziemssen T, Thomas K.
Verlag
Ther Adv Neurol Disord 2017;10(10):343-359.
Zum Eintrag
“Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis” Multiple Sclerosis and Related Disorders 2017
Link
https://doi.org/10.1016/j.msard.2017.07.019
Tags
Multiple Sklerose
MS Behandlung
Jahr
2017
Autoren
Thomas K, Ziemssen T.
Verlag
Mult Scler Relat Disord 2017;17:177-178.
Zum Eintrag
Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
Link
https://doi.org/10.3389/fnins.2017.00540
Tags
Multiple Sklerose
MS Behandlung
Autonomes Nervensystem & Neuroendokrinologie
Herzratenvariabilität
Baroreflexsensitivität
Jahr
2017
Autoren
Li K, Konofalska U, Akgün K, Reimann M, Rüdiger H, Haase R, Ziemssen T.
Verlag
Front Neurosci. 2017 Oct 12;11:540.
Zum Eintrag
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion
Link
https://doi.org/10.1080/14656566.2017.1367383
Tags
Multiple Sklerose
MS Behandlung
Jahr
2017
Autoren
D’Amico E, Ziemssen T, Cottone S.
Verlag
Expert Opin Pharmacother 2017;18(15):1553-1556.
Zum Eintrag
16
17
18
19
20
Publikationen durchsuchen
Publikationen filtern
Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show All
Hide
Jahr
-